ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DFTX vs BTI // PIOTROSKI F-SCORE QUALITY

Definium Therapeutics Inc. (NASDAQ) VS. British American Tobacco Industries p.l.c. ADR (NYSE) • 15-METRIC TALLY: DFTX 3 — BTI 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: BTI
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DFTX VS. BTI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DFTX BTI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.20% 9.90% -42.10 BTI /roic <GO>
EV/EBITDA & P/E Valuation — 21.0x — TIE /valuation <GO>
Free Cash Flow Yield -3.84% 2.21% -6.05 BTI /fcf-yield <GO>
Operating Margin -11.60% 13.90% -25.50 BTI /operating-margins <GO>
Net Profit Margin -12.90% 10.90% -23.80 BTI /net-margins <GO>
Revenue Growth (YoY) 5.50% 0.00% +5.50 DFTX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 3.74 +22.26 DFTX /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 5/9 7/9 -2.00 BTI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.4 65.7 -10.30 BTI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.08 1.05 +0.03 DFTX /macro-sensitivity <GO>
Forward P/E Multiple 33.0x 30.5x +2.50 BTI /forward-pe <GO>
Enterprise Scale & Market Cap $5.10B $131.93B -$126.83B BTI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DFTX REV BTI REV DFTX GROSS % BTI GROSS % DFTX FCF BTI FCF
FY 2025 $0 — — — -$131.6M —
FY 2024 $0 — — — -$79.1M —
FY 2023 $0 — — — -$64.4M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DFTX // BETA 1.08
BTI // BETA 1.05